Guido Tricot
Concepts (542)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 139 | 2024 | 3035 | 9.200 |
Why?
| Hematopoietic Stem Cell Transplantation | 27 | 2024 | 573 | 3.750 |
Why?
| Pyrazines | 20 | 2023 | 203 | 2.870 |
Why?
| Boronic Acids | 19 | 2014 | 197 | 2.650 |
Why?
| Thalidomide | 28 | 2023 | 397 | 2.610 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 34 | 2024 | 1056 | 2.520 |
Why?
| Antineoplastic Agents | 29 | 2020 | 1300 | 1.990 |
Why?
| Transplantation, Autologous | 27 | 2024 | 476 | 1.860 |
Why?
| Transplantation Conditioning | 9 | 2019 | 86 | 1.590 |
Why?
| Drug Resistance, Neoplasm | 16 | 2020 | 309 | 1.560 |
Why?
| Paraproteinemias | 8 | 2018 | 80 | 1.380 |
Why?
| Neoplastic Stem Cells | 5 | 2020 | 103 | 1.270 |
Why?
| Humans | 149 | 2024 | 54284 | 1.170 |
Why?
| Protease Inhibitors | 6 | 2011 | 64 | 1.160 |
Why?
| Venous Thrombosis | 7 | 2009 | 102 | 1.110 |
Why?
| Angiogenesis Inhibitors | 9 | 2009 | 203 | 1.050 |
Why?
| Melphalan | 15 | 2023 | 180 | 1.030 |
Why?
| Hematopoietic Stem Cell Mobilization | 5 | 2014 | 61 | 1.010 |
Why?
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 866 | 0.990 |
Why?
| Aged | 57 | 2023 | 10054 | 0.990 |
Why?
| Busulfan | 3 | 2019 | 18 | 0.920 |
Why?
| Alkaline Phosphatase | 5 | 2011 | 99 | 0.910 |
Why?
| Prognosis | 31 | 2024 | 2118 | 0.900 |
Why?
| Stem Cell Transplantation | 12 | 2023 | 196 | 0.870 |
Why?
| Middle Aged | 56 | 2023 | 13088 | 0.870 |
Why?
| Plasma Cells | 10 | 2023 | 238 | 0.820 |
Why?
| Treatment Outcome | 37 | 2022 | 5604 | 0.790 |
Why?
| Dexamethasone | 15 | 2024 | 435 | 0.760 |
Why?
| Thromboembolism | 3 | 2009 | 56 | 0.710 |
Why?
| Male | 63 | 2021 | 27334 | 0.670 |
Why?
| Neoplasm Proteins | 6 | 2021 | 359 | 0.670 |
Why?
| Female | 59 | 2021 | 28441 | 0.630 |
Why?
| Immunoglobulin Light Chains | 3 | 2016 | 101 | 0.620 |
Why?
| Bone Remodeling | 2 | 2010 | 177 | 0.600 |
Why?
| Anticoagulants | 5 | 2009 | 270 | 0.600 |
Why?
| Blood Transfusion | 1 | 2018 | 138 | 0.590 |
Why?
| Immunologic Factors | 5 | 2012 | 130 | 0.580 |
Why?
| Gene Expression Profiling | 18 | 2023 | 1138 | 0.580 |
Why?
| Cell Line, Tumor | 18 | 2023 | 1550 | 0.550 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 27 | 0.550 |
Why?
| Follow-Up Studies | 21 | 2024 | 2387 | 0.540 |
Why?
| IMP Dehydrogenase | 2 | 2006 | 4 | 0.540 |
Why?
| Proteasome Inhibitors | 6 | 2018 | 110 | 0.540 |
Why?
| Mycophenolic Acid | 2 | 2006 | 17 | 0.540 |
Why?
| Survival Rate | 16 | 2019 | 951 | 0.520 |
Why?
| Clinical Trials as Topic | 8 | 2022 | 490 | 0.510 |
Why?
| Cell Proliferation | 15 | 2020 | 1096 | 0.500 |
Why?
| Adult | 37 | 2018 | 14207 | 0.500 |
Why?
| Antineoplastic Agents, Alkylating | 6 | 2008 | 74 | 0.500 |
Why?
| Recurrence | 15 | 2018 | 690 | 0.490 |
Why?
| Up-Regulation | 5 | 2020 | 508 | 0.480 |
Why?
| Osteogenesis | 3 | 2012 | 377 | 0.470 |
Why?
| Chromosome Aberrations | 7 | 2008 | 316 | 0.470 |
Why?
| Venous Thromboembolism | 3 | 2011 | 75 | 0.470 |
Why?
| Disease-Free Survival | 11 | 2019 | 485 | 0.470 |
Why?
| Retrospective Studies | 18 | 2024 | 6432 | 0.470 |
Why?
| Combined Modality Therapy | 12 | 2008 | 692 | 0.470 |
Why?
| Apoptosis | 9 | 2019 | 1300 | 0.460 |
Why?
| Doxorubicin | 8 | 2018 | 259 | 0.460 |
Why?
| Antibodies, Monoclonal | 3 | 2015 | 562 | 0.460 |
Why?
| Disease Progression | 12 | 2019 | 913 | 0.450 |
Why?
| Animals | 30 | 2024 | 14385 | 0.450 |
Why?
| Signal Transduction | 12 | 2020 | 1753 | 0.450 |
Why?
| Survival Analysis | 11 | 2021 | 735 | 0.450 |
Why?
| Antigens, Neoplasm | 4 | 2007 | 170 | 0.440 |
Why?
| Bone Diseases | 3 | 2012 | 109 | 0.440 |
Why?
| Central Nervous System Neoplasms | 2 | 2004 | 57 | 0.440 |
Why?
| Thrombosis | 4 | 2012 | 243 | 0.440 |
Why?
| Myeloablative Agonists | 5 | 2014 | 33 | 0.420 |
Why?
| Transplantation, Homologous | 6 | 2004 | 155 | 0.410 |
Why?
| Oligopeptides | 2 | 2013 | 95 | 0.410 |
Why?
| Bone Marrow | 7 | 2022 | 411 | 0.410 |
Why?
| T-Lymphocytes | 9 | 2024 | 373 | 0.410 |
Why?
| Osteoblasts | 4 | 2007 | 514 | 0.400 |
Why?
| Hematopoietic Stem Cells | 2 | 2010 | 215 | 0.390 |
Why?
| Risk Factors | 18 | 2018 | 3935 | 0.390 |
Why?
| Meta-Analysis as Topic | 2 | 2015 | 39 | 0.380 |
Why?
| Salvage Therapy | 9 | 2012 | 145 | 0.380 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2008 | 69 | 0.380 |
Why?
| Chromosomes, Human, Pair 13 | 4 | 2008 | 41 | 0.380 |
Why?
| Ultrasonography, Doppler | 2 | 2007 | 57 | 0.360 |
Why?
| Enzyme Inhibitors | 2 | 2019 | 446 | 0.360 |
Why?
| Membrane Proteins | 4 | 2017 | 389 | 0.360 |
Why?
| Mice | 19 | 2024 | 6413 | 0.360 |
Why?
| Neoplasm, Residual | 4 | 2022 | 166 | 0.350 |
Why?
| Remission Induction | 9 | 2008 | 221 | 0.340 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 199 | 0.340 |
Why?
| B-Lymphocytes | 4 | 2021 | 176 | 0.340 |
Why?
| Prospective Studies | 9 | 2019 | 2604 | 0.340 |
Why?
| Myelodysplastic Syndromes | 3 | 2007 | 79 | 0.340 |
Why?
| Waldenstrom Macroglobulinemia | 3 | 2018 | 41 | 0.340 |
Why?
| Lymphoma, B-Cell | 3 | 2021 | 62 | 0.330 |
Why?
| Immunosuppressive Agents | 3 | 2005 | 248 | 0.330 |
Why?
| Bone Neoplasms | 1 | 2010 | 193 | 0.330 |
Why?
| Neovascularization, Pathologic | 1 | 2009 | 168 | 0.320 |
Why?
| Brain Diseases, Metabolic | 1 | 2007 | 7 | 0.310 |
Why?
| Hyperammonemia | 1 | 2007 | 18 | 0.300 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 131 | 0.300 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 108 | 0.300 |
Why?
| Farnesyltranstransferase | 1 | 2006 | 5 | 0.300 |
Why?
| Thrombophilia | 4 | 2009 | 20 | 0.300 |
Why?
| Amyloidosis | 2 | 2007 | 85 | 0.300 |
Why?
| Peripheral Blood Stem Cell Transplantation | 4 | 2014 | 57 | 0.290 |
Why?
| Small Molecule Libraries | 2 | 2019 | 72 | 0.290 |
Why?
| Hemostasis | 1 | 2007 | 56 | 0.290 |
Why?
| Dose-Response Relationship, Drug | 6 | 2016 | 1476 | 0.290 |
Why?
| Aged, 80 and over | 11 | 2019 | 3431 | 0.290 |
Why?
| Research Design | 1 | 2009 | 374 | 0.290 |
Why?
| Immunotherapy, Adoptive | 4 | 2024 | 134 | 0.290 |
Why?
| Bone and Bones | 1 | 2010 | 516 | 0.290 |
Why?
| Sirolimus | 1 | 2006 | 65 | 0.280 |
Why?
| Gastrointestinal Neoplasms | 1 | 2006 | 46 | 0.280 |
Why?
| Cell Survival | 8 | 2018 | 657 | 0.270 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2016 | 278 | 0.270 |
Why?
| Diploidy | 2 | 2004 | 30 | 0.260 |
Why?
| Caspases | 1 | 2006 | 146 | 0.260 |
Why?
| Flow Cytometry | 6 | 2018 | 546 | 0.260 |
Why?
| Antibody Formation | 1 | 2005 | 69 | 0.260 |
Why?
| Activated Protein C Resistance | 4 | 2011 | 10 | 0.260 |
Why?
| Killer Cells, Natural | 3 | 2012 | 107 | 0.250 |
Why?
| Religion | 1 | 2005 | 68 | 0.250 |
Why?
| Enoxaparin | 1 | 2004 | 25 | 0.250 |
Why?
| Chromosome Deletion | 2 | 2008 | 150 | 0.250 |
Why?
| Aneuploidy | 1 | 2004 | 23 | 0.250 |
Why?
| Ubiquitination | 2 | 2021 | 47 | 0.240 |
Why?
| Adaptation, Psychological | 1 | 2005 | 244 | 0.240 |
Why?
| Attitude to Health | 1 | 2005 | 226 | 0.230 |
Why?
| Osteolysis | 2 | 2022 | 88 | 0.230 |
Why?
| Pyrimidines | 3 | 2015 | 196 | 0.230 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2012 | 596 | 0.220 |
Why?
| Cancer Vaccines | 3 | 2010 | 103 | 0.220 |
Why?
| Blood Coagulation | 1 | 2003 | 69 | 0.220 |
Why?
| Mice, Inbred NOD | 6 | 2020 | 99 | 0.220 |
Why?
| Antigens, CD34 | 1 | 2003 | 80 | 0.220 |
Why?
| Graft vs Host Disease | 5 | 2010 | 83 | 0.220 |
Why?
| Leukemia, Myeloid | 1 | 2002 | 54 | 0.210 |
Why?
| STAT3 Transcription Factor | 4 | 2015 | 87 | 0.210 |
Why?
| Critical Illness | 1 | 2005 | 344 | 0.210 |
Why?
| Chromosome Disorders | 1 | 2002 | 39 | 0.210 |
Why?
| Bone Resorption | 2 | 2022 | 326 | 0.210 |
Why?
| Parathyroid Hormone | 3 | 2010 | 196 | 0.210 |
Why?
| Case-Control Studies | 9 | 2018 | 1228 | 0.210 |
Why?
| Neoplasms, Second Primary | 1 | 2002 | 77 | 0.200 |
Why?
| Hypothyroidism | 1 | 2002 | 53 | 0.200 |
Why?
| Antibodies, Bispecific | 1 | 2022 | 43 | 0.200 |
Why?
| Kidney | 1 | 2007 | 820 | 0.200 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 93 | 0.200 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2006 | 113 | 0.200 |
Why?
| Neoplasm Recurrence, Local | 4 | 2024 | 644 | 0.190 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2019 | 219 | 0.180 |
Why?
| Multivariate Analysis | 4 | 2008 | 643 | 0.180 |
Why?
| Glucuronidase | 2 | 2018 | 48 | 0.180 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 462 | 0.180 |
Why?
| Neoplasms | 2 | 2009 | 1316 | 0.180 |
Why?
| Cisplatin | 5 | 2009 | 352 | 0.170 |
Why?
| Predictive Value of Tests | 5 | 2009 | 1048 | 0.170 |
Why?
| Bone Marrow Transplantation | 4 | 2007 | 149 | 0.170 |
Why?
| Syndecan-1 | 3 | 2017 | 82 | 0.170 |
Why?
| Cytotoxicity, Immunologic | 2 | 2012 | 62 | 0.170 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 158 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 271 | 0.170 |
Why?
| Hydrocarbons, Aromatic | 1 | 2018 | 3 | 0.170 |
Why?
| Kaplan-Meier Estimate | 6 | 2015 | 514 | 0.170 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.170 |
Why?
| Solvents | 1 | 2018 | 35 | 0.170 |
Why?
| Jehovah's Witnesses | 1 | 2018 | 7 | 0.160 |
Why?
| Tumor Microenvironment | 2 | 2023 | 209 | 0.160 |
Why?
| Cytogenetic Analysis | 5 | 2007 | 90 | 0.160 |
Why?
| Pyridines | 1 | 2019 | 137 | 0.160 |
Why?
| Time Factors | 8 | 2016 | 3213 | 0.160 |
Why?
| Vincristine | 3 | 2003 | 98 | 0.160 |
Why?
| Cyclophosphamide | 3 | 2003 | 172 | 0.160 |
Why?
| CDC2-CDC28 Kinases | 2 | 2015 | 15 | 0.160 |
Why?
| Platelet Count | 3 | 2008 | 77 | 0.160 |
Why?
| Cell Differentiation | 4 | 2022 | 720 | 0.160 |
Why?
| Cytokines | 3 | 2007 | 676 | 0.160 |
Why?
| beta 2-Microglobulin | 3 | 2008 | 35 | 0.150 |
Why?
| Logistic Models | 4 | 2018 | 995 | 0.150 |
Why?
| Occupational Diseases | 1 | 2018 | 93 | 0.150 |
Why?
| Iron | 2 | 2017 | 158 | 0.150 |
Why?
| Etoposide | 4 | 2009 | 85 | 0.150 |
Why?
| Dendritic Cells | 2 | 2010 | 142 | 0.150 |
Why?
| Risk Assessment | 5 | 2023 | 1361 | 0.150 |
Why?
| Drug Combinations | 1 | 2017 | 128 | 0.150 |
Why?
| Pyruvate Kinase | 1 | 2017 | 8 | 0.150 |
Why?
| Ascorbic Acid | 1 | 2017 | 33 | 0.150 |
Why?
| Mice, SCID | 5 | 2018 | 196 | 0.150 |
Why?
| Interleukin-6 | 2 | 2018 | 315 | 0.150 |
Why?
| Occupational Exposure | 1 | 2018 | 129 | 0.150 |
Why?
| Anthropometry | 1 | 2017 | 96 | 0.150 |
Why?
| RNA Splicing | 1 | 2017 | 38 | 0.150 |
Why?
| Glycolysis | 1 | 2017 | 73 | 0.140 |
Why?
| Factor V | 3 | 2011 | 11 | 0.140 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2016 | 18 | 0.140 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.140 |
Why?
| Tumor Cells, Cultured | 6 | 2019 | 477 | 0.140 |
Why?
| Transcription Factors | 1 | 2020 | 622 | 0.140 |
Why?
| Fibrinolytic Agents | 2 | 2007 | 139 | 0.140 |
Why?
| Reproductive History | 1 | 2015 | 4 | 0.140 |
Why?
| Incidence | 3 | 2009 | 1082 | 0.140 |
Why?
| Leukocytes, Mononuclear | 2 | 2014 | 133 | 0.140 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 18 | 0.140 |
Why?
| MicroRNAs | 1 | 2020 | 386 | 0.140 |
Why?
| Hormone Replacement Therapy | 1 | 2015 | 27 | 0.140 |
Why?
| Cyclopentanes | 1 | 2015 | 14 | 0.130 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 87 | 0.130 |
Why?
| Ubiquitins | 1 | 2015 | 40 | 0.130 |
Why?
| Hemorrhage | 2 | 2007 | 208 | 0.130 |
Why?
| Cation Transport Proteins | 1 | 2015 | 28 | 0.130 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 130 | 0.130 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 27 | 0.130 |
Why?
| Immunotherapy | 3 | 2006 | 263 | 0.130 |
Why?
| Postmenopause | 1 | 2015 | 102 | 0.130 |
Why?
| Hematologic Neoplasms | 1 | 2016 | 99 | 0.130 |
Why?
| Drug Monitoring | 1 | 2015 | 85 | 0.130 |
Why?
| NF-kappa B | 3 | 2018 | 335 | 0.130 |
Why?
| Osteoclasts | 3 | 2022 | 469 | 0.130 |
Why?
| Leukapheresis | 1 | 2014 | 16 | 0.120 |
Why?
| Transplantation Chimera | 3 | 2003 | 15 | 0.120 |
Why?
| Protein-Tyrosine Kinases | 1 | 2015 | 101 | 0.120 |
Why?
| Translocation, Genetic | 3 | 2005 | 287 | 0.120 |
Why?
| Myeloma Proteins | 2 | 2020 | 26 | 0.120 |
Why?
| Intestines | 1 | 2016 | 204 | 0.120 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 24 | 0.120 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.120 |
Why?
| Gene Deletion | 3 | 2004 | 293 | 0.120 |
Why?
| Antibodies | 2 | 2024 | 178 | 0.120 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 19 | 0.120 |
Why?
| Isoxazoles | 1 | 2013 | 16 | 0.120 |
Why?
| Body Mass Index | 1 | 2017 | 713 | 0.120 |
Why?
| Sulfones | 1 | 2013 | 24 | 0.120 |
Why?
| Hedgehog Proteins | 1 | 2013 | 33 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 21 | 0.120 |
Why?
| Itraconazole | 1 | 2013 | 45 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2016 | 552 | 0.120 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 72 | 0.120 |
Why?
| Metaphase | 3 | 2008 | 55 | 0.120 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 75 | 0.110 |
Why?
| Biopsy | 2 | 2006 | 692 | 0.110 |
Why?
| Carrier Proteins | 2 | 2017 | 359 | 0.110 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 570 | 0.110 |
Why?
| T-Lymphocytes, Cytotoxic | 2 | 2010 | 72 | 0.110 |
Why?
| Wnt Proteins | 1 | 2013 | 110 | 0.110 |
Why?
| Renal Insufficiency | 3 | 2009 | 138 | 0.110 |
Why?
| Risk | 2 | 2011 | 343 | 0.110 |
Why?
| Viremia | 1 | 2012 | 25 | 0.110 |
Why?
| Drug Delivery Systems | 2 | 2005 | 151 | 0.110 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 46 | 0.110 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2012 | 48 | 0.100 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 51 | 0.100 |
Why?
| Receptors, KIR | 2 | 2008 | 15 | 0.100 |
Why?
| Reoperation | 2 | 2004 | 454 | 0.100 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2021 | 205 | 0.100 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 238 | 0.100 |
Why?
| Medical Oncology | 1 | 2012 | 102 | 0.100 |
Why?
| Phosphorylation | 2 | 2020 | 614 | 0.100 |
Why?
| Ligands | 2 | 2009 | 230 | 0.100 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 158 | 0.100 |
Why?
| Alcohol Drinking | 1 | 2013 | 259 | 0.100 |
Why?
| Inflammation | 1 | 2016 | 674 | 0.100 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.100 |
Why?
| Arsenicals | 1 | 2010 | 14 | 0.100 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 21 | 0.100 |
Why?
| Oxides | 1 | 2010 | 19 | 0.100 |
Why?
| Age Factors | 3 | 2005 | 1198 | 0.100 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2007 | 49 | 0.090 |
Why?
| Janus Kinase 1 | 1 | 2010 | 20 | 0.090 |
Why?
| Recombinant Proteins | 2 | 2010 | 569 | 0.090 |
Why?
| Smoking | 1 | 2014 | 556 | 0.090 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 26 | 0.090 |
Why?
| Cyclin-Dependent Kinases | 1 | 2010 | 35 | 0.090 |
Why?
| Authorship | 1 | 2010 | 14 | 0.090 |
Why?
| Macrophages | 1 | 2013 | 405 | 0.090 |
Why?
| Down-Regulation | 2 | 2010 | 388 | 0.090 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 101 | 0.090 |
Why?
| Conflict of Interest | 1 | 2010 | 24 | 0.090 |
Why?
| Drug Industry | 1 | 2010 | 40 | 0.090 |
Why?
| Neoplasm Staging | 3 | 2015 | 806 | 0.090 |
Why?
| Disclosure | 1 | 2010 | 39 | 0.090 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 83 | 0.090 |
Why?
| Diphosphonates | 1 | 2010 | 96 | 0.090 |
Why?
| Chromosome Banding | 2 | 2006 | 28 | 0.090 |
Why?
| Leukocyte Count | 2 | 2014 | 77 | 0.090 |
Why?
| Maximum Tolerated Dose | 2 | 2009 | 37 | 0.090 |
Why?
| Plasmacytoma | 2 | 2011 | 47 | 0.090 |
Why?
| Mice, Transgenic | 3 | 2021 | 656 | 0.090 |
Why?
| Periodicals as Topic | 1 | 2010 | 65 | 0.080 |
Why?
| Tretinoin | 1 | 2009 | 56 | 0.080 |
Why?
| Cryoglobulinemia | 1 | 2008 | 12 | 0.080 |
Why?
| Cell Cycle | 2 | 2010 | 275 | 0.080 |
Why?
| Magnetic Resonance Imaging | 3 | 2007 | 1604 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2014 | 474 | 0.080 |
Why?
| Blotting, Western | 3 | 2015 | 683 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 28 | 0.080 |
Why?
| Prednisone | 2 | 2009 | 111 | 0.080 |
Why?
| Neutrophils | 2 | 2014 | 154 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 230 | 0.080 |
Why?
| Pulmonary Embolism | 1 | 2009 | 106 | 0.080 |
Why?
| Hemoglobins | 1 | 2008 | 126 | 0.080 |
Why?
| Immunophenotyping | 2 | 2007 | 117 | 0.080 |
Why?
| Sulfonamides | 1 | 2009 | 146 | 0.080 |
Why?
| Polyethylene Glycols | 1 | 2008 | 106 | 0.080 |
Why?
| Adoptive Transfer | 1 | 2007 | 38 | 0.080 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2007 | 21 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 673 | 0.080 |
Why?
| Histocompatibility Antigens Class I | 1 | 2007 | 52 | 0.080 |
Why?
| Phlebography | 1 | 2007 | 70 | 0.080 |
Why?
| Fibrinolysis | 1 | 2007 | 8 | 0.080 |
Why?
| Ammonia | 1 | 2007 | 73 | 0.080 |
Why?
| Blood Coagulation Factors | 1 | 2007 | 19 | 0.070 |
Why?
| Chi-Square Distribution | 1 | 2007 | 318 | 0.070 |
Why?
| Biomedical Research | 1 | 2010 | 240 | 0.070 |
Why?
| Osteoprotegerin | 1 | 2006 | 57 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2006 | 401 | 0.070 |
Why?
| Cell Membrane | 1 | 2007 | 278 | 0.070 |
Why?
| Guanosine | 1 | 2006 | 6 | 0.070 |
Why?
| Brain | 2 | 2007 | 1387 | 0.070 |
Why?
| Antibiotics, Antineoplastic | 1 | 2006 | 85 | 0.070 |
Why?
| Models, Genetic | 1 | 2006 | 209 | 0.070 |
Why?
| Sex Factors | 3 | 2016 | 767 | 0.070 |
Why?
| Femur Head Necrosis | 1 | 2005 | 17 | 0.070 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 72 | 0.070 |
Why?
| Guanosine Triphosphate | 1 | 2004 | 23 | 0.060 |
Why?
| Renal Dialysis | 1 | 2007 | 192 | 0.060 |
Why?
| Karyotyping | 1 | 2005 | 92 | 0.060 |
Why?
| Gene Duplication | 1 | 2005 | 17 | 0.060 |
Why?
| Survivors | 1 | 2006 | 137 | 0.060 |
Why?
| Tissue Donors | 2 | 2003 | 110 | 0.060 |
Why?
| Oncogene Proteins, Fusion | 1 | 2005 | 60 | 0.060 |
Why?
| Kidney Transplantation | 1 | 2007 | 188 | 0.060 |
Why?
| Thrombophlebitis | 1 | 2004 | 28 | 0.060 |
Why?
| Proteolysis | 2 | 2015 | 102 | 0.060 |
Why?
| Genomic Instability | 1 | 2005 | 95 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 53 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 82 | 0.060 |
Why?
| RNA Interference | 2 | 2015 | 195 | 0.060 |
Why?
| Anxiety | 1 | 2005 | 279 | 0.060 |
Why?
| Discitis | 1 | 2003 | 8 | 0.060 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2004 | 377 | 0.060 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 12 | 0.060 |
Why?
| Confidence Intervals | 1 | 2003 | 167 | 0.060 |
Why?
| Patient Selection | 1 | 2005 | 286 | 0.060 |
Why?
| Probability | 1 | 2003 | 176 | 0.060 |
Why?
| Neoplastic Cells, Circulating | 1 | 2004 | 93 | 0.060 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| Interferons | 1 | 2002 | 44 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2003 | 231 | 0.060 |
Why?
| Cyclosporine | 1 | 2003 | 66 | 0.050 |
Why?
| Cell Count | 1 | 2003 | 181 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2002 | 54 | 0.050 |
Why?
| Thyroid Function Tests | 1 | 2002 | 25 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 426 | 0.050 |
Why?
| Tacrolimus | 1 | 2003 | 52 | 0.050 |
Why?
| Geography | 1 | 2022 | 81 | 0.050 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 4 | 0.050 |
Why?
| ABO Blood-Group System | 1 | 2002 | 14 | 0.050 |
Why?
| Thyrotropin | 1 | 2002 | 46 | 0.050 |
Why?
| Administration, Oral | 1 | 2003 | 459 | 0.050 |
Why?
| Drug Interactions | 1 | 2002 | 206 | 0.050 |
Why?
| Fatal Outcome | 1 | 2002 | 225 | 0.050 |
Why?
| Chromosome Mapping | 3 | 2006 | 175 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 330 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| Graft Survival | 1 | 2002 | 165 | 0.050 |
Why?
| Genomics | 1 | 2023 | 310 | 0.050 |
Why?
| Acute Disease | 1 | 2002 | 403 | 0.050 |
Why?
| Cluster Analysis | 3 | 2006 | 249 | 0.050 |
Why?
| Cells, Cultured | 1 | 2005 | 1737 | 0.050 |
Why?
| Young Adult | 3 | 2015 | 4318 | 0.050 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1213 | 0.050 |
Why?
| Neoplasm Transplantation | 1 | 2020 | 94 | 0.050 |
Why?
| Depression | 1 | 2005 | 595 | 0.050 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 57 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 604 | 0.050 |
Why?
| Postoperative Complications | 1 | 2007 | 1033 | 0.040 |
Why?
| Pain | 1 | 2003 | 405 | 0.040 |
Why?
| Staphylococcal Infections | 1 | 2003 | 300 | 0.040 |
Why?
| Positron-Emission Tomography | 1 | 2021 | 322 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 178 | 0.040 |
Why?
| Antigens, CD | 2 | 2015 | 242 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 226 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 283 | 0.040 |
Why?
| Coculture Techniques | 2 | 2012 | 160 | 0.040 |
Why?
| Antigens, CD19 | 1 | 2018 | 19 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2019 | 368 | 0.040 |
Why?
| Bone Marrow Cells | 2 | 2015 | 233 | 0.040 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 29 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 74 | 0.040 |
Why?
| Microarray Analysis | 1 | 2018 | 84 | 0.040 |
Why?
| Disease Management | 1 | 2020 | 184 | 0.040 |
Why?
| Protein Stability | 1 | 2018 | 44 | 0.040 |
Why?
| Interferon-gamma | 2 | 2010 | 195 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2018 | 125 | 0.040 |
Why?
| Epidemiologic Methods | 2 | 2008 | 49 | 0.040 |
Why?
| Aerobiosis | 1 | 2017 | 16 | 0.040 |
Why?
| Microfilament Proteins | 1 | 2017 | 47 | 0.040 |
Why?
| Thyroid Hormones | 1 | 2017 | 18 | 0.040 |
Why?
| Transplantation, Heterologous | 1 | 2017 | 77 | 0.040 |
Why?
| HLA-A Antigens | 2 | 2007 | 13 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 61 | 0.040 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2016 | 3 | 0.040 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 3 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 1693 | 0.040 |
Why?
| Vaccination | 2 | 2010 | 294 | 0.040 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 55 | 0.040 |
Why?
| Genetic Loci | 1 | 2016 | 58 | 0.040 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 25 | 0.040 |
Why?
| Antibodies, Neoplasm | 2 | 2006 | 35 | 0.030 |
Why?
| Protein Binding | 1 | 2018 | 736 | 0.030 |
Why?
| Mice, Knockout | 1 | 2018 | 926 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 87 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 28 | 0.030 |
Why?
| Genome-Wide Association Study | 1 | 2016 | 190 | 0.030 |
Why?
| Tumor Burden | 1 | 2016 | 142 | 0.030 |
Why?
| ras Proteins | 1 | 2015 | 70 | 0.030 |
Why?
| Receptors, Transferrin | 1 | 2015 | 17 | 0.030 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.030 |
Why?
| Lentivirus | 1 | 2015 | 18 | 0.030 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.030 |
Why?
| Repressor Proteins | 1 | 2016 | 165 | 0.030 |
Why?
| Adenine | 1 | 2015 | 44 | 0.030 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 7 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 128 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 6 | 0.030 |
Why?
| Family | 1 | 2016 | 193 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| RNA, Messenger | 2 | 2010 | 1202 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 23 | 0.030 |
Why?
| Cell Lineage | 1 | 2014 | 93 | 0.030 |
Why?
| Reactive Oxygen Species | 1 | 2017 | 491 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2013 | 1639 | 0.030 |
Why?
| Models, Biological | 1 | 2018 | 823 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 102 | 0.030 |
Why?
| Drug Synergism | 1 | 2014 | 171 | 0.030 |
Why?
| Piperidines | 1 | 2015 | 103 | 0.030 |
Why?
| Mitosis | 1 | 2014 | 106 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2014 | 142 | 0.030 |
Why?
| Pyrazoles | 1 | 2015 | 110 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 271 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2006 | 431 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 29 | 0.030 |
Why?
| Patient Safety | 1 | 2014 | 121 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 22 | 0.030 |
Why?
| Chromosomal Instability | 1 | 2013 | 17 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 89 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 216 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 55 | 0.030 |
Why?
| Adolescent | 2 | 2014 | 6897 | 0.030 |
Why?
| Immunoglobulin M | 1 | 2012 | 65 | 0.030 |
Why?
| Cytomegalovirus | 1 | 2012 | 30 | 0.030 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 10 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 11 | 0.030 |
Why?
| Virus Activation | 1 | 2012 | 30 | 0.030 |
Why?
| Viral Load | 1 | 2012 | 85 | 0.030 |
Why?
| Interleukin-2 | 1 | 2012 | 75 | 0.030 |
Why?
| Peripheral Nervous System Diseases | 1 | 2012 | 63 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 165 | 0.030 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.030 |
Why?
| Arkansas | 2 | 2008 | 2100 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2011 | 43 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2012 | 125 | 0.030 |
Why?
| Protein C | 1 | 2011 | 23 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 119 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2012 | 197 | 0.030 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2010 | 24 | 0.020 |
Why?
| Antiviral Agents | 1 | 2012 | 188 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 15 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 18 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 48 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 80 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 61 | 0.020 |
Why?
| Physician's Role | 1 | 2010 | 55 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2010 | 252 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2004 | 1136 | 0.020 |
Why?
| Education, Medical, Continuing | 1 | 2010 | 80 | 0.020 |
Why?
| Hyperhomocysteinemia | 1 | 2009 | 30 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 492 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 124 | 0.020 |
Why?
| Indazoles | 1 | 2009 | 55 | 0.020 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 31 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1501 | 0.020 |
Why?
| Vasculitis | 1 | 2008 | 30 | 0.020 |
Why?
| Safety | 1 | 2009 | 92 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 13 | 0.020 |
Why?
| Algorithms | 1 | 2012 | 697 | 0.020 |
Why?
| Haplotypes | 1 | 2008 | 105 | 0.020 |
Why?
| Serum Albumin | 1 | 2008 | 62 | 0.020 |
Why?
| Twins | 1 | 2007 | 32 | 0.020 |
Why?
| Double-Blind Method | 1 | 2009 | 742 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2008 | 159 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2007 | 116 | 0.020 |
Why?
| Creatinine | 1 | 2007 | 169 | 0.020 |
Why?
| Partial Thromboplastin Time | 1 | 2006 | 12 | 0.020 |
Why?
| Blood Proteins | 1 | 2007 | 100 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 20 | 0.020 |
Why?
| Syndecans | 1 | 2006 | 43 | 0.020 |
Why?
| Heterozygote | 1 | 2006 | 96 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 54 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 54 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| Amiloride | 1 | 2005 | 14 | 0.020 |
Why?
| Proteoglycans | 1 | 2006 | 96 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2005 | 50 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 191 | 0.020 |
Why?
| Cell Communication | 1 | 2006 | 72 | 0.020 |
Why?
| Radiography | 1 | 2007 | 524 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 177 | 0.020 |
Why?
| Cell Line | 1 | 2008 | 1153 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 115 | 0.020 |
Why?
| Interferon-alpha | 1 | 2005 | 50 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 923 | 0.020 |
Why?
| Monocytes | 1 | 2005 | 156 | 0.020 |
Why?
| Membrane Glycoproteins | 1 | 2006 | 269 | 0.020 |
Why?
| Databases, Factual | 1 | 2007 | 684 | 0.020 |
Why?
| Clone Cells | 1 | 2004 | 89 | 0.020 |
Why?
| Monosomy | 1 | 2003 | 5 | 0.010 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 240 | 0.010 |
Why?
| Trisomy | 1 | 2003 | 34 | 0.010 |
Why?
| History, 21st Century | 1 | 2003 | 62 | 0.010 |
Why?
| Fibroblasts | 1 | 2005 | 386 | 0.010 |
Why?
| History, 20th Century | 1 | 2003 | 114 | 0.010 |
Why?
| Interphase | 1 | 2003 | 14 | 0.010 |
Why?
| Plasmapheresis | 1 | 2003 | 14 | 0.010 |
Why?
| Back Pain | 1 | 2003 | 44 | 0.010 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 9 | 0.010 |
Why?
| United States | 1 | 2013 | 5217 | 0.010 |
Why?
| Anemia | 1 | 2003 | 84 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1543 | 0.010 |
Why?
| Prevalence | 1 | 2005 | 1025 | 0.010 |
Why?
| Quality Assurance, Health Care | 1 | 2003 | 164 | 0.010 |
Why?
| DNA, Neoplasm | 1 | 2002 | 171 | 0.010 |
Why?
| Erythrocyte Transfusion | 1 | 2002 | 74 | 0.010 |
Why?
| Graft Rejection | 1 | 2002 | 161 | 0.010 |
Why?
| Kidney Diseases | 1 | 2003 | 293 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2003 | 820 | 0.010 |
Why?
|
|
Tricot's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|